MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) major shareholder Anson Funds Management Lp bought 48,060 shares of MEI Pharma stock in a transaction that occurred on Friday, September 22nd. The shares were acquired at an average cost of $6.85 per share, for a total transaction of $329,211.00. Following the acquisition, the insider now owns 864,188 shares in the company, valued at approximately $5,919,687.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Anson Funds Management Lp also recently made the following trade(s):
- On Wednesday, September 20th, Anson Funds Management Lp purchased 120,000 shares of MEI Pharma stock. The shares were acquired at an average price of $6.01 per share, with a total value of $721,200.00.
MEI Pharma Stock Down 1.7 %
Shares of NASDAQ MEIP opened at $7.42 on Tuesday. The firm’s fifty day moving average is $6.45 and its 200 day moving average is $6.91. MEI Pharma, Inc. has a 52 week low of $4.00 and a 52 week high of $8.74. The company has a market cap of $49.42 million, a price-to-earnings ratio of -1.34 and a beta of 0.95.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on MEIP
Hedge Funds Weigh In On MEI Pharma
Hedge funds have recently modified their holdings of the company. Simplex Trading LLC purchased a new stake in shares of MEI Pharma during the second quarter worth about $28,000. BML Capital Management LLC purchased a new stake in MEI Pharma in the 2nd quarter worth approximately $151,000. BNP Paribas Arbitrage SA lifted its holdings in MEI Pharma by 483.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 62,963 shares of the company’s stock worth $38,000 after buying an additional 52,169 shares during the period. MetLife Investment Management LLC grew its position in shares of MEI Pharma by 969.4% in the 1st quarter. MetLife Investment Management LLC now owns 79,966 shares of the company’s stock worth $48,000 after buying an additional 72,488 shares during the last quarter. Finally, Mirabella Financial Services LLP purchased a new position in shares of MEI Pharma during the first quarter valued at approximately $76,000. Hedge funds and other institutional investors own 41.92% of the company’s stock.
MEI Pharma Company Profile
MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- What Investors Need to Know to Beat the Market
- 2 Must-Have Silicon Companies That Don’t Make Microchips
- Stock Dividend Cuts Happen Are You Ready?
- Small Caps That Have Priced In A Hard Landing For Big Upside
- Breakout Stocks: What They Are and How to Identify Them
- This May Have Ended Alibaba’s Winter, But Is It Time To Buy?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
